Luxembourg biotech Usil Therapeutics lands €5.2M EU grant for radiation treatment
What's the deal? Luxembourg-based biotech startup Usil Therapeutics has secured a €5.2M grant from the European Commission under the Hera/EU4Health programme to develop what it describes as Europe's first universal medical countermeasure for radiation exposure.
The project scored 93 out of 100 in the Commission's evaluation. It also received the Step label, a designation reserved for technologies deemed strategic to European sovereignty.
Usil is incubated at Luxembourg's City Incubator and leads a consortium backed by the CEA, a top European nuclear research body. The goal: move its molecule into the industrial phase with a delivery system designed for emergencies — usable even by non-medical staff.
Why now? There is currently no treatment available in the EU for acute radiation syndrome. That gap has become harder to ignore amid rising geopolitical tensions and persistent nuclear risks across the continent.
"This selection by the European Commission and Hera highlights the urgent need to provide Europe with autonomous solutions that can be deployed on a large scale," said Frédéric Marin, Usil's chief executive officer. "Our ambition is to bridge the gap between cutting-edge biotechnology and real-world operational needs."
What could go wrong? Turning a promising molecule into a mass-produced, field-ready treatment is a long road. Biotech timelines are notoriously unpredictable, and regulatory hurdles for medical countermeasures — especially those intended for emergency deployment — can be steep. The company will also need to prove it can scale manufacturing to meet the continent-wide demand it's targeting.
The signal: This grant reflects a broader EU push to build domestic capabilities in health security and defence-adjacent technologies, reducing reliance on non-European suppliers. Usil sits at the intersection of healthcare, defence, and space — a niche that's attracting growing political and financial attention as Europe rethinks sovereignty across critical sectors.
For Luxembourg, it reinforces the country's quiet emergence as a deep-tech hub where industrial ambition meets strategic policy priorities.
Read more: delano.lu
